★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Agilent Technologies, Inc. (A) Moat Analysis
Agilent Technologies, Inc.
A · New York Stock Exchange
Partial score covering 81% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Agilent is a life-sciences and analytical-tools company selling lab instruments, consumables, software and services. Its defensible advantages are qualification and revalidation costs in regulated workflows, recurring consumables and pathology reagents around installed platforms, CrossLab service coverage, and embedded laboratory informatics. The June 25, 2026 Biocare acquisition expands recurring pathology antibodies and reagents inside Life Sciences and Diagnostics. CrossLab reported 32.0% Q2 FY2026 operating margin, but field-service density is not quantified enough for a top score. Applied Markets has no separately evidenced moat because its instrument categories face strong oligopoly competition and consumables were moved to CrossLab in the segment reorganization. General reliability and support competition are not sufficient evidence of brand trust.
Primary segment
Agilent CrossLab
Market structure
Competitive
Market share
—
HHI: —
Coverage
3 segments · 6 tags
Updated 2026-07-12
Segments
Life Sciences and Diagnostics Markets
Life science and clinical lab analytical instruments, software and consumables (chromatography, mass spectrometry, pathology and genomics workflows)
Revenue
39.2%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Agilent CrossLab
Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow
Revenue
41.9%
Structure
Competitive
Pricing
strong
Share
—
Peers
Applied Markets
Applied chemical analysis instruments (GC/GCMS, spectroscopy, vacuum) and related consumables for environmental, food, forensics, and industrial labs
Revenue
18.9%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Life Sciences and Diagnostics Markets
Life science and clinical lab analytical instruments, software and consumables (chromatography, mass spectrometry, pathology and genomics workflows)
FY25 net revenue $2,726M (39.2343% of total) and segment income from operations $536M (19.7% op margin). Derived from Agilent Q4 FY25 Financial Information (segment results) https://s24.q4cdn.com/305549747/files/doc_earnings/2025/q4/supplemental-info/Q4-25-Financial-Information-Final.pdf.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Instrument platforms and software are embedded in regulated/validated lab workflows (QA/QC, method validation). Switching often requires revalidation, retraining and downtime planning.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Customers adopt multi-vendor standardized methods and data formats
- Performance parity and aggressive pricing from major rivals
- Capex cycles shift toward lower-cost alternatives or leasing
Leading indicators
- LC/LCMS installed-base share trend vs peers
- Gross margin trend and discounting intensity
- Win/loss rates in top pharma and clinical accounts
Counterarguments
- Large labs periodically re-qualify alternative vendors during planned validation cycles
- Third-party integration layers reduce dependence on any single OEM
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Recurring pull-through from consumables and parts (e.g., chromatography columns, sample prep, standards, replacement parts) tied to the installed instrument base and workflow.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Third-party compatible columns and parts take share on price
- Customer standardization on generic consumables
- Budget pressure drives mix to lower-margin supplies
Leading indicators
- Consumables revenue growth vs instrument revenue growth
- Attach-rate and reorder frequency in top platforms
- Distributor/e-commerce mix shift
Counterarguments
- Many consumables are compatible across vendors and compete heavily on price
- Labs may source standardized consumables via distributors to reduce vendor dependence
Agilent CrossLab
Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow
FY25 net revenue $2,908M (41.8538% of total) and segment income from operations $946M (32.5% op margin). Derived from Agilent Q4 FY25 Financial Information (segment results) https://s24.q4cdn.com/305549747/files/doc_earnings/2025/q4/supplemental-info/Q4-25-Financial-Information-Final.pdf.
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Service contracts, preventative maintenance and compliance services benefit from scale and proximity to a large installed base; OEM service reduces downtime risk for regulated labs.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Third-party service providers undercut OEM pricing
- Customers insource maintenance or extend replacement cycles
- Remote diagnostics reduces need for dense field network
Leading indicators
- Service contract renewal rate and attach rate
- CrossLab operating margin trend
- Backlog and services revenue growth vs installed base growth
Counterarguments
- Independent service organizations can service many instruments at lower cost
- Customers may accept longer downtime to reduce service spend
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Lab informatics (instrument control, data capture/analysis, compliant data storage) becomes embedded in SOPs, integrations and audit trails - raising switching and retraining costs.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Customers standardize on vendor-neutral LIMS/ELN layers
- Open formats/APIs reduce switching friction
- Cybersecurity or data-integrity incidents weaken trust
Leading indicators
- Informatics subscription/ARR disclosures (if provided)
- Churn/renewal commentary on software offerings
- Growth of integrations/partners on the platform
Counterarguments
- Many labs prefer independent LIMS/ELN vendors as the system of record
- Procurement can treat instrument software as replaceable if data export is robust
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Broad chemistries, supplies and lab automation consumables attach to recurring lab spend; CrossLab also benefits from parts and supplies tied to the instrument installed base.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Distributor/private-label competition compresses margins
- Customers consolidate spend with full-line distributors
- Consumables shift to standardized/generic alternatives
Leading indicators
- CrossLab revenue mix (consumables vs services vs software) if disclosed
- Gross margin trend and price/mix commentary
- Share in key consumables categories (e.g., columns) via third-party data
Counterarguments
- Many consumables are readily substitutable and priced competitively
- Large customers can force vendor-neutral supply contracts
Applied Markets
Applied chemical analysis instruments (GC/GCMS, spectroscopy, vacuum) and related consumables for environmental, food, forensics, and industrial labs
FY25 net revenue $1,314M (18.9119% of total) and segment income from operations $301M (22.9% op margin). Derived from Agilent Q4 FY25 Financial Information (segment results) https://s24.q4cdn.com/305549747/files/doc_earnings/2025/q4/supplemental-info/Q4-25-Financial-Information-Final.pdf.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
Describes OpenLab software enabling compliant instrument use in pharmaceutical QA/QC environments (supports inference of validation-driven switching costs).
States LC and LC/MS platforms are part of the Life Sciences and Diagnostics Markets segment after the Nov 2024 reorganization.
Provides FY25 segment revenue ($2,726M) and segment operating margin (~19.7%) used to contextualize pricing power.
solutions that include reagents, instruments, software and consumables
Current filing places integrated reagents and consumables for cell analysis, imaging, pathology and genomics within this segment.
Biocare is now part of Agilent's Life Sciences and Diagnostics Markets Group
Biocare adds a recurring pathology antibody and reagent portfolio alongside instruments in this segment.
Showing 5 of 10 sources.
Risks & Indicators
Erosion risks
- Customers adopt multi-vendor standardized methods and data formats
- Performance parity and aggressive pricing from major rivals
- Capex cycles shift toward lower-cost alternatives or leasing
- Third-party compatible columns and parts take share on price
- Customer standardization on generic consumables
- Budget pressure drives mix to lower-margin supplies
Leading indicators
- LC/LCMS installed-base share trend vs peers
- Gross margin trend and discounting intensity
- Win/loss rates in top pharma and clinical accounts
- Consumables revenue growth vs instrument revenue growth
- Attach-rate and reorder frequency in top platforms
- Distributor/e-commerce mix shift
Research A elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.